Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Regulatory Breakthrough and Market Opportunities: SS Innovations International, Inc. (SSII) Announces That Its SSI Mantra Surgical Robotic System Has Recently Received Approval from Regulatory Authorities in Indonesia and the Philippines, Officially Entering the Telesurgery Markets of Both Countries

Regulatory Breakthrough and Market Opportunities: SS Innovations International, Inc. (SSII) Announces That Its SSI Mantra Surgical Robotic System Has Recently Received Approval from Regulatory Authorities in Indonesia and the Philippines, Officially Entering the Telesurgery Markets of Both Countries

老虎证券老虎证券2026/03/18 13:00
Show original
This breakthrough marks a further opening of market access policies for medical technology in the Asia-Pacific region, providing new growth opportunities for multinational medical device companies. **Technical Advantages and Clinical Value** The SSI Mantra system features high-precision robotic arms and real-time image navigation capabilities, enabling surgeons to perform remote operations across regions via 5G networks. The system has completed over a thousand clinical surgeries in India, covering complex procedures in urology, gynecology, and other specialties, with its safety and efficacy initially validated. Following this approval, medical institutions in Indonesia and the Philippines can directly adopt this technology, helping to alleviate the uneven distribution of high-end medical resources locally. **Asia-Pacific Medical Technology Competitive Landscape** In recent years, the surgical robotics market in the Asia-Pacific region has been dominated by the da Vinci system from international giant Intuitive Surgical, but local companies are rapidly catching up through cost-effectiveness and localized services. Indonesia and the Philippines have a combined population of over 400 million, yet there are fewer than 0.5 surgical robots per million people, far below the levels in Europe and the US (about 5-10 units). This market access breakthrough for SSII may stimulate more regional medical technology companies to accelerate technology exports and compliance strategies. **Industry Trends and Capital Focus** The global remote surgery market is expected to exceed $20 billion by 2028, with a compound annual growth rate of 15%. Southeast Asian countries have recently begun to relax approval processes for digital medical devices; for example, Thailand revised its Medical Device Act in 2023, and Vietnam has included remote surgery in its health insurance pilot program. In the secondary market, the medical technology sector has recently been boosted by the AI+Healthcare concept, with several institutions raising ratings for related companies. SSII’s recent approval may provide new momentum for its business expansion in the Asia-Pacific region, but attention should be paid to the subsequent pace of commercialization and cash flow performance.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Morningstar expects Woodside's revenue growth will outpace global peers by the end of this decade

On October 9, Morningstar predicted that the revenue of Australian oil and gas producer Woodside Energy (WDS.AX) will grow by over 30% by 2030, outpacing any of its international peers. Woodside Energy’s share price dropped by 0.6% on the day to 32.12 AUD, after surging 2.6% in the previous trading session. The stock is poised to end a three-week losing streak, with oil prices rising due to escalating tensions in the Middle East, and is set for a 2.8% weekly gain O/R. Morningstar expects Woodside’s revenue to increase as major new projects come online, and forecasts free cash flow to exceed 7 billion USD after 2030, reflecting a 300% rise from 2025. The report added that market sentiment remains bearish, with the current share price below its estimated fair value of 44.00 AUD. Year-to-date, Woodside’s share price has risen 36.2%, while Santos shares are up 41.3%. (For the convenience of non-English speakers, Reuters has automated the translation of its reports into several languages. Since automated translations may be inaccurate or lack required context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for the convenience of readers. Reuters accepts no liability for any loss or damage arising from your use of automated translation functions.)

路透社•2026/10/09 02:16

Star analyst Ives: Bullish on Apple (AAPL.US) up to $400, AI strategy may increase valuation by $75 per share

Ives has given Apple stock an "outperform" rating, with a target price of $400.

智通财经•2026/10/09 02:01

New York gold prices rose on the 8th

新浪财经•2026/10/09 01:36

BUZZ - After the turmoil of Firmus' initial public offering, Australia's Maas Group shares plunged nearly 30% this week

October 9 - ** Shares of Australian Maas Group (MGH.AX) have fallen more than 27% so far this week and are set for their worst weekly performance if the downward trend continues. ** On Thursday, media reported that Firmus, backed by Nvidia, might reduce the size of its AUD 5 billion Australian IPO (link), sparking investor concerns and leading to a 30% plunge in shares of construction services provider MGH. ** MGH holds a 3.2% stake in this AI data center operator. ** MGH suspended trading on Friday (link), pending an announcement related to Firmus. Firmus has shelved its AUD 5 billion listing plan due to market volatility and conditions. ** Before the suspension, MGH's shares had already fallen over 8% this year. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. This automated translation may contain inaccuracies or omit the desired context; Reuters does not guarantee the accuracy of automated translations and provides them solely for reader convenience. Reuters accepts no liability for any harm or loss caused by the use of automated translations.)

路透社•2026/10/09 01:26